AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22311006
Drug: Welding fumes
RxNorm normalized name: Aluminum welding fumes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Welding fumes exposure at 1 mg/m(3) for 6 hours
Trial: 22311006
Drug: Welding fumes
RxNorm normalized name: Aluminum welding fumes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Welding fumes exposure at 2.5 mg/m(3) for 6 hours
Trial: 22311006
Drug: Ambient air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambient air exposure (0 mg/m(3)) for 6 hours
Trial: 18359422
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving new antibiotics during the surveillance period
Trial: 18359422
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not on antibiotics
Trial: 18359422
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on no new antibiotics
Trial: 18359422
Drug: Potential antibiotic
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential antibiotic error rates
Trial: 11716192
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (2.5 mg, i.e., 100,000 IU) administered orally at three specific periods (end of September, November, and January)
Trial: 11716192
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vitamin D3 treatment)
Trial: 8424419
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg over 20 min)
Trial: 2434546
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol 17-propionate cream applied twice daily for 1 week
Trial: 18412782
Drug: Dry tablet
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry tablet insertion of vaginal misoprostol (400 microg)
Trial: 18412782
Drug: Gel form
RxNorm normalized name: Timoptic-XE 0.5 % Gel Forming Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel form of vaginal misoprostol (400 microg)
Trial: 12377965
Drug: 2-hour daily
RxNorm normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour daily infusion of ara-C 500 mg/m(2)/d and 2-CdA 9 mg/m(2)/d (arm A)
Trial: 12377965
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ara-C 500 mg/m(2)/d and 2-CdA 9 mg/m(2)/d (arm B)
Trial: 12377965
Drug: Toxicity incidence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxicity incidence between treatment arms
Trial: 10085671
Drug: Oral Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Granisetron 1 mg
Trial: 30272231
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg) once daily for 14 days
Trial: 30272231
Drug: Darunavir/cobicistat (800/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/cobicistat (800/150 mg) once daily for 14 days
Trial: 30272231
Drug: Dolutegravir/darunavir/cobicistat (DTG/DRV/COBI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir/darunavir/cobicistat (DTG/DRV/COBI) once daily
Trial: 21394686
Drug: Transgingival antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgingival antibacterial photodynamic therapy (PDT)
Trial: 21394686
Drug: Control site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control site rinsed with ringer solution
Trial: 17031264
Drug: Oral dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dipyridamole 200 mg twice daily for 24 weeks
Trial: 12974986
Drug: Nemifitide (re-treatment)
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nemifitide (re-treatment)
Trial: 12974986
Drug: Nemifitide (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemifitide (initial treatment)
Trial: 22661752
Drug: i.v. MgSO(4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. MgSO(4) at a dose of 50 mg kg(‐1) diluted in 100 ml 0.9% saline solution followed by 15 mg kg(‐1) h(‐1) for 6 h
Trial: 22661752
Drug: Saline at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline at the same volume [mean (sd) 64 (10) ml]
Trial: 10801253
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg daily for 6 months
Trial: 30843231
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control (no PDL treatment)
Trial: 12087350
Drug: S21402 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S21402 (250 mg)
Trial: 7872387
Drug: Topical fibronectin
RxNorm normalized name: Fibronectin
DrugBank: Fibronectin (DB15150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fibronectin ophthalmic solution (3.5 mg/ml)
Trial: 7872387
Drug: Vehicle drops
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle drops from the fibronectin solution
Trial: 2404368
Drug: Ceftazidime 500
RxNorm normalized name: ceftazidime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 500 mg twice daily for five days
Trial: 2404368
Drug: Moxalactam 500
RxNorm normalized name: Moxalactam
DrugBank: Moxalactam (hydrolyzed) (DB04740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam 500 mg twice daily for five days
Trial: 358727
Drug: Paracervical blocks
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical blocks administered to PGF2alpha-treated patients
Trial: 358727
Drug: No paracervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No paracervical blocks administered to PGF2alpha-treated patients
Trial: 358727
Drug: Paracervical blocks
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical blocks administered to saline-treated patients
Trial: 358727
Drug: No paracervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No paracervical blocks administered to saline-treated patients
Trial: 31339827
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant chemotherapy (physician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin)
Trial: 26028929
Drug: Rifaximin treatment
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin treatment for 4 weeks (n = 36)
Trial: 26028929
Drug: Rifaximin treatment
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin treatment for 8 weeks (n = 43)
Trial: 26028929
Drug: Rifaximin treatment
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin treatment for 12 weeks (n = 23)
Trial: 26028929
Drug: Rifaximin treatment
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin treatment for 4 weeks vs 12 weeks
Trial: 26028929
Drug: Rifaximin treatment
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin treatment for all periods
Trial: 23818710
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment strategies (tight control)
Trial: 23818710
Drug: Less intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intensive treatment strategies
Trial: 18942777
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment for rheumatoid arthritis
Trial: 18942777
Drug: Existing treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing treatments
Trial: 16963040
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: recombinant hFSH from day 3 until follicles reached 13‐14 mm, then lowered to 75 IU daily, with daily injections of 200 IU of hCG and a GnRH antagonist until final maturation
Trial: 16963040
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: recombinant hFSH and a GnRH antagonist
Trial: 16963040
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: recombinant hFSH and a GnRH agonist
Trial: 14599958
Drug: Enzyme supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme supplementation therapy
Trial: 1533455
Drug: Amoxicillin 25
RxNorm normalized name: amoxicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 25 mg/kg/day divided into two doses for 3 months
Trial: 1533455
Drug: Glycoproteins from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoproteins from Klebsiella pneumoniae (GKP) 2 tablets per day during 8 days in the 1st month and 1 tablet per day during 8 days in the following 2 months
Trial: 3889259
Drug: Intratracheal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratracheal administration of human surfactant
Trial: 3889259
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with intermittent mandatory ventilation
Trial: 31557127
Drug: Oral aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aromatase inhibitors (AIs)
Trial: 31557127
Drug: Subcutaneous daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous daily growth hormone (GH)
Trial: 31557127
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (AI/GH)
Trial: 8198064
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation (500 mg, three times a day) for 5 of the 10 weeks
Trial: 29982870
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion chemotherapy (HAIC)
Trial: 26544615
Drug: Evidence-based decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based decision support for depression treatment
Trial: 23989915
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 2-3 mg/kg per day
Trial: 23989915
Drug: Mesalazine 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 3.2 g per day
Trial: 19270470
Drug: Day clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day clinic treatment
Trial: 16549463
Drug: CLA-diet rich
RxNorm normalized name: CLA
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLA-diet rich in CLA (4.7 g/d of c9,t11- and t10,c12-CLA isomers in equal amounts)
Trial: 16549463
Drug: VA-diet rich
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VA-diet rich in VA (3.6 g/d)
Trial: 8420411
Drug: Heparin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (25 U/kg) administered intravenously 10 min before challenge
Trial: 8420411
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (20,000 units) administered 10 min before challenge
Trial: 3310589
Drug: Moricizine HCl
RxNorm normalized name: moricizine HCl
DrugBank: Moricizine (DB00680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine HCl therapy
Trial: 29862568
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention therapy combined with routine medications
Trial: 15729225
Drug: Midazolam 7.5
RxNorm normalized name: midazolam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 7.5 mg orally
Trial: 12893326
Drug: OXY‐TDS 3.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXY‐TDS 3.9 mg/day
Trial: 12893326
Drug: TOL‐LA 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOL‐LA 4 mg/day
Trial: 9467472
Drug: Piroxicam FDDF
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam FDDF (40 mg sublingual)
Trial: 9467472
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (75 mg intramuscular)
Trial: 7874912
Drug: Critical care
RxNorm normalized name: Adult critical care formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critical care medicine elective consisting of orientation, interactive conferences, technical skills laboratories, daily rounds, and patient-care experience.
Trial: 2089356
Drug: Naftidrofuryl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (2 x 200 mg/day for 6 weeks)
Trial: 30219027
Drug: Scalp nerves
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine (Group LA)
Trial: 30219027
Drug: Scalp nerves
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine plus 15 IU/ml Hyaluronidase (Group H)
Trial: 27308644
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (esomeprazole 20 mg, twice daily)
Trial: 27308644
Drug: Double-dose therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose therapy (esomeprazole 40 mg, twice daily)
Trial: 12464464
Drug: Amisulpride (400-1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (400-1,000 mg/day)
Trial: 2290711
Drug: Ceftriaxone (Cef)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (Cef) 2 g daily infusion
Trial: 2290711
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) 2 g daily infusion
Trial: 31961463
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus megestrol acetate (MA) - MA (160 mg orally, daily) plus metformin (500 mg orally, three times a day)
Trial: 31961463
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) alone - MA (160 mg orally, daily)
Trial: 31961463
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus MA in AEH patients
Trial: 31961463
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus MA in non-obese AEH patients
Trial: 31961463
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus MA in insulin-sensitive AEH patients
Trial: 24225216
Drug: PCT monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT monitoring in guiding the use of antibiotics group (PCT group, n=42)
Trial: 24225216
Drug: Regular antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular antibiotic therapy group (RAT group, n=40)
Trial: 11377651
Drug: Local activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local activation of low-dose ifosfamide using encapsulated genetically modified allogeneic cells delivered by supraselective angiography
Trial: 9517370
Drug: Gemfibrozil, 600
RxNorm normalized name: Gemfibrozil, 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil, 600 mg twice daily
Trial: 9517370
Drug: Lovastatin, 40
RxNorm normalized name: Lovastatin, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin, 40 mg daily
Trial: 8278467
Drug: Siltex textured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltex textured inflatable implant
Trial: 8278467
Drug: Smooth inflatable
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smooth inflatable implant
Trial: 2662695
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (3 g/day)
Trial: 27429374
Drug: Half-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose group (3 mg/m verteporfin, 83 seconds laser light)
Trial: 27429374
Drug: Half-fluence group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-fluence group (6 mg/m verteporfin, 42 seconds laser light)
Trial: 21910334
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine treatment (insulin and anti-diabetic drugs)
Trial: 6422900
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate or monoamine oxidase (MAO) inhibitors
Trial: 6422900
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (TCA) and second-generation antidepressants
Trial: 25286703
Drug: Ultrasound-guided facet
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided facet joint injection
Trial: 25286703
Drug: Blindly administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blindly administered facet joint block
Trial: 22811444
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (85% cocoa, 0.55 g/kg body wt)
Trial: 20600400
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 20% (w/w) HPMC
Trial: 20600400
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 40% (w/w) HPMC
Trial: 20600400
Drug: Tablets with
RxNorm normalized name: Aconitum napellus/Evening Trumpetflower/Onion/Zinc Gluconate 6 X-6 X-6 X-2 X Sublingual Tablet [HYLAND'S COLD TABLETS WITH ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with lower concentration of HPMC and higher lactose concentration
Trial: 17646513
Drug: ropivacaine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.05% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Trial: 17646513
Drug: ropivacaine 0.075%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.075% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Trial: 17646513
Drug: ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.1% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Trial: 16286872
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg.kg(‐1) body mass)
Trial: 12670087
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg minocycline hydrochloride (Arestin) administered at baseline, three and six months
Trial: 7654482
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg once a day for 2 months
Trial: 31684867
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine bolus 1.5 mg/kg at induction followed by an infusion (1.5 mg/kg/h)
Trial: 31684867
Drug: IV esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV esmolol bolus 0.5 mg/kg at induction followed by an infusion (5-15 μg/kg/min)
Trial: 26679480
Drug: Budesonide respules
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide respules via mucosal atomization device (MAD) twice daily
Trial: 26679480
Drug: Budesonide respules
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide respules instilled via vertex-to-floor (VF) position twice daily
Trial: 26679480
Drug: Fluticasone nasal
RxNorm normalized name: fluticasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray twice daily